Omeros Corporation Grants Performance-Based Stock Options to CEO
Omeros Corporation has awarded CEO Gregory A. Demopulos a performance-based stock option grant for up to 500,000 shares, with vesting tied to specific stock-price milestones.
Stocks · News reference
Omeros shares are trading lower after the company announced that the EMA’s CHMP issued a negative opinion on its marketing authorization application for narsoplimab in TA-TMA, following re-examination of its original negative opinion adopted in June 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — OMEROS CORP (OMER)
Filed: 2026-10-30 AccNo: 0001552781-26-000531 Size: 270 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Truist Financial, Regions Financial And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures mixed; Truist slips after mixed results, while Telkom Indonesia, Loma Negra, Omeros and others fall premarket.
Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
Omeros shares are trading lower Friday after the company announced that the EMA’s CHMP upheld its negative opinion on narsoplimab for TA-TMA.
Omeros Receives EMA CHMP Negative Opinion On Its Marketing Authorization Application For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Decision follows re-examination of its original negative opinion adopted in June 2026. An eight-member ad hoc expert group (AHEG) consisting of hematologists, statisticians, and transplant physicians, together with two
Cantor Fitzgerald Reiterates Overweight on Omeros, Maintains $22 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Omeros (NASDAQ:OMER) with a Overweight and maintains $22 price target.